Cargando…

The tumor mutational landscape of BRCA2-deficient primary and metastatic prostate cancer

Carriers of germline BRCA2 pathogenic sequence variants have elevated aggressive prostate cancer risk and are candidates for precision oncology treatments. We examined whether BRCA2-deficient (BRCA2(d)) prostate tumors have distinct genomic alterations compared with BRCA2-intact (BRCA2(i)) tumors. A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kensler, Kevin H., Baichoo, Shakuntala, Pathania, Shailja, Rebbeck, Timothy R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205939/ https://www.ncbi.nlm.nih.gov/pubmed/35715489 http://dx.doi.org/10.1038/s41698-022-00284-6

Ejemplares similares

Discovering novel driver mutations from pan-cancer analysis of mutational and gene expression profiles
por: Tegally, Houriiyah, et al.
Publicado: (2020)

Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Rebbeck, Timothy R, et al.
Publicado: (2008)

Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers
por: Rebbeck, Timothy R., et al.
Publicado: (2009)

Roles of the PARP Inhibitor in BRCA1 and BRCA2 Pathogenic Mutated Metastatic Prostate Cancer: Direct Functions and Modification of the Tumor Microenvironment
por: Inoue, Takahiro, et al.
Publicado: (2023)

The germline mutational landscape of BRCA1 and BRCA2 in Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2018)

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype
por: Fettke, Heidi, et al.
Publicado: (2023)

Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry
por: Yuan, Jiao, et al.
Publicado: (2020)

BRCA1 haploinsufficiency for replication stress suppression in primary cells
por: Pathania, Shailja, et al.
Publicado: (2014)

The Somatic Mutational Landscape of Mismatch Repair Deficient Prostate Cancer
por: Fang, Bangwei, et al.
Publicado: (2023)

The Landscape of BRCA Mutations among Egyptian Women with Breast Cancer
por: Azim, Hamdy A., et al.
Publicado: (2023)

E3 ligase RFWD3 is a novel modulator of stalled fork stability in BRCA2-deficient cells
por: Duan, Haohui, et al.
Publicado: (2020)

Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA
por: Swami, Umang, et al.
Publicado: (2022)

The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers
por: Cavanagh, Helen, et al.
Publicado: (2015)

The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited
por: Deek, Matthew P., et al.
Publicado: (2021)

Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
por: Koguchi, Dai, et al.
Publicado: (2021)

Mutations in BRCA2 and taxane resistance in prostate cancer
por: Nientiedt, Cathleen, et al.
Publicado: (2017)

BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications
por: Messina, Carlo, et al.
Publicado: (2020)

BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored
por: Crocetto, Felice, et al.
Publicado: (2021)

BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside
por: Boussios, Stergios, et al.
Publicado: (2022)

Characteristics of BRCA2 Mutated Prostate Cancer at Presentation
por: Han, Hyunho, et al.
Publicado: (2022)

Penetrance of Breast and Ovarian Cancer in Women Who Carry a BRCA1/2 Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis
por: Chen, Jinbo, et al.
Publicado: (2020)

Physiological modulation of endogenous BRCA1 p220 abundance suppresses DNA damage during the cell cycle
por: Dimitrov, Stoil D., et al.
Publicado: (2013)

Breast and ovarian cancer penetrance of BRCA1/2 mutations among Hong Kong women
por: Zhang, LingJiao, et al.
Publicado: (2018)

Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
por: Ma, Yi, et al.
Publicado: (2018)

The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel
por: Vazina, A, et al.
Publicado: (2000)

Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations
por: Bancroft, Elizabeth K., et al.
Publicado: (2018)

Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
por: Birkbak, Nicolai Juul, et al.
Publicado: (2013)

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA
por: Matsubara, Nobuaki, et al.
Publicado: (2023)

MMR-deficiency and BRCA2/EGFR/NTRK mutations
por: Gokare, Prashanth, et al.
Publicado: (2017)

Germline BRCA1 mutations increase prostate cancer risk
por: Leongamornlert, D, et al.
Publicado: (2012)

Analysis of BRCA Germline Mutations in Chinese Prostate Cancer Patients
por: Chen, Wei, et al.
Publicado: (2022)

BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations
por: Shah, Sidrah, et al.
Publicado: (2021)

Genomic Landscape of Actionable Mutations in Primary and Metastatic Tissues of Colon Adenocarcinoma
por: Yekedüz, Emre, et al.
Publicado: (2022)

Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A Case Report
por: Julka, Pramod Kumar, et al.
Publicado: (2020)

Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing
por: Nogueira Costa, Inês, et al.
Publicado: (2022)

Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer
por: Su, Christopher T., et al.
Publicado: (2022)

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
por: Abida, Wassim, et al.
Publicado: (2020)

Predominance of BRCA2 Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with BRCA1 or BRCA2 Mutation
por: Pujol, Pascal, et al.
Publicado: (2022)

Treatment Options for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma
por: Grzelak, Doreen
Publicado: (2021)

The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
por: Lundberg, Arian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pqlt5rsfm0rr76142k9t4asj2h